<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Megestrol acetate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Megestrol acetate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Megestrol acetate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10835" href="/d/html/10835.html" rel="external">see "Megestrol acetate: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12578" href="/d/html/12578.html" rel="external">see "Megestrol acetate: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F192314"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Megace ES [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F192330"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Hormone;</li>
<li>
                        Appetite Stimulant;</li>
<li>
                        Progestin</li></ul></div>
<div class="block doa drugH1Div" id="F192316"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Megestrol suspensions are not equivalent on a mg-per-mg basis.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="80cde1c9-b392-4705-aca8-a82d0ae81102">Anorexia or cachexia associated with AIDS</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anorexia or cachexia associated with AIDS:</b> Suspension: Initial: <b>Oral: </b>625 mg daily (of the 125 mg/mL suspension) or 800 mg daily (of the 40 mg/mL suspension); daily doses of 400 mg to 800 mg have been found to be effective.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70f72d8d-3f95-478a-a281-8d0e7521cd98">Breast cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced:</b> Tablet: <b>Oral: </b>160 mg per day in divided doses of 40 mg 4 times daily for at least 2 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8edf0a5-60ec-4726-9477-5ef05e725995">Cancer-related cachexia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cancer-related cachexia (off-label use):</b>
<b>Oral:</b> 200 to 600 mg/day; duration of treatment depends on treatment goals and risk/benefit assessment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32432946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32432946'])">Ref</a></span>). In studies, doses ranging from 160 to 800 mg/day were effective in achieving weight gain; higher doses (&gt;160 mg) were associated with more weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9137798','lexi-content-ref-2193166','lexi-content-ref-8478668','lexi-content-ref-10506633','lexi-content-ref-9708631']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9137798','lexi-content-ref-2193166','lexi-content-ref-8478668','lexi-content-ref-10506633','lexi-content-ref-9708631'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="520deb5b-1dde-4119-8880-c68d483f2680">Endometrial cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial cancer, advanced:</b> Tablet: <b>Oral: </b>40 to 320 mg daily in divided doses for at least 2 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f621d71a-8117-4e4f-bd21-24c888bb8911">Endometrial hyperplasia, alternative therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial hyperplasia, alternative therapy (off-label use):</b> Tablet: <b>Oral:</b> 40 to 200 mg/day for atypical endometrial hyperplasia/endometrial intraepithelial neoplasia; megestrol may be administered continuously or cyclical. The optimal dose and duration have not been established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25932867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25932867'])">Ref</a></span>). Surgical treatment is recommended if response is not observed within 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33604759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33604759'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991807"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;30 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤30 mL/minute: <b>Note:</b> Megestrol is primarily eliminated in the urine; use with caution.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>Initial: Start with doses at the lower end of the recommended indication-specific dose range; may titrate to the usual recommended indication-specific dose based on response and tolerability. Monitor frequently for adverse effects (eg, edema, hyperglycemia, adrenal insufficiency, venous thromboembolism). Doses of up to 800 mg/day taken for up to 6 months have been used for the treatment of cachexia in patients with severe kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23349204','lexi-content-ref-34286938','lexi-content-ref-26776251','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23349204','lexi-content-ref-34286938','lexi-content-ref-26776251','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b>
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): <b>Oral:</b> Dose as for CrCl ≤30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): <b>Oral:</b> Dose as for CrCl ≤30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>
<b>Oral:</b> Dose as for CrCl ≤30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>
<b>Oral:</b> Dose as for CrCl ≤30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989083"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F192317"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F52812530"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12578" href="/d/html/12578.html" rel="external">see "Megestrol acetate: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Megestrol oral suspension is available in 2 concentrations (40 mg/mL and 125 mg/mL [eg, Megace ES]); they are not equivalent on a mg-per-mg basis; precautions should be taken to verify and avoid confusion between the different concentrations; in pediatric trials including liquid formulations, only the 40 mg/mL has been used.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b3410a5-1cda-4beb-9079-aff5303bff81">Appetite stimulant/anorexia associated with chronic illness</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Appetite stimulant/anorexia associated with chronic illness (eg, cancer, cystic fibrosis, HIV):</b> Limited data available; efficacy results variable:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥8 months, Children, and Adolescents: Oral: Tablets or 40 mg/mL suspension: Initial dose: 7.5 to 10 mg/kg/day in 1 to 2 divided doses; in patients &gt;10 years, daily doses divided into 4 doses have been used; titrate dose to response; maximum daily dose: 15 mg/kg/<b>day</b> not to exceed 800 mg/<b>day</b>. Monitor patients closely for adverse effects, particularly adrenal suppression.</p>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on several prospective and retrospective trials and case series. Clinical trials show benefit for weight gain and body (non-muscle) mass (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8853762','lexi-content-ref-7970985','lexi-content-ref-9041287','lexi-content-ref-24167059','lexi-content-ref-12006958','lexi-content-ref-20430646','lexi-content-ref-10997370','lexi-content-ref-10536070','lexi-content-ref-12872362','lexi-content-ref-Ullrich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8853762','lexi-content-ref-7970985','lexi-content-ref-9041287','lexi-content-ref-24167059','lexi-content-ref-12006958','lexi-content-ref-20430646','lexi-content-ref-10997370','lexi-content-ref-10536070','lexi-content-ref-12872362','lexi-content-ref-Ullrich.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729766"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, the urinary excretion of megestrol acetate is substantial; use caution.</p></div>
<div class="block dohp drugH1Div" id="F52729767"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F58341334"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Adrenal insufficiency</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Megestrol may be associated with hypothalamic-pituitary-adrenal (<b>HPA)-axis suppression</b> that may be difficult to differentiate due to comorbid conditions or concurrent therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35851863','lexi-content-ref-27218795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35851863','lexi-content-ref-27218795'])">Ref</a></span>). HPA-axis suppression may be life threatening, but discontinuation of megestrol and/or treatment with a corticosteroid typically resolves symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23412818','lexi-content-ref-26770843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23412818','lexi-content-ref-26770843'])">Ref</a></span>). Symptom resolution in case reports varies from days to months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baby.2021','lexi-content-ref-23412818','lexi-content-ref-27218795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baby.2021','lexi-content-ref-23412818','lexi-content-ref-27218795'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; megestrol activates both progesterone and glucocorticoid receptors (GR) and has a stronger binding affinity than its endogenous counterparts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23412818','lexi-content-ref-26770843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23412818','lexi-content-ref-26770843'])">Ref</a></span>). Dual agonist/antagonist behavior is exhibited by megestrol binding to the GR as a weak agonist, then simultaneously blocking endogenous glucocorticoids to the GR (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baby.2021','lexi-content-ref-23412818','lexi-content-ref-26770843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baby.2021','lexi-content-ref-23412818','lexi-content-ref-26770843'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; reports range from days to months and has been reported during therapy and following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baby.2021','lexi-content-ref-23412818','lexi-content-ref-26770843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baby.2021','lexi-content-ref-23412818','lexi-content-ref-26770843'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation of megestrol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26770843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26770843'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent therapies that may impair HPA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26770843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26770843'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Intercurrent acute stress or illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23412818','lexi-content-ref-26770843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23412818','lexi-content-ref-26770843'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Venous thromboembolism</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Megestrol may be associated with <b>venous thromboembolism</b> (VTE); the exact incidence is difficult to quantify, given confounding risk factors such as concurrent chemotherapy/radiotherapy and tumor-induced hypercoagulability, but has been cited as &lt;5% to 11% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11727356','lexi-content-ref-25556442','lexi-content-ref-23543530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11727356','lexi-content-ref-25556442','lexi-content-ref-23543530'])">Ref</a></span>). Megestrol is on the Beers List of Potentially Inappropriate Medication Use in Older Adults due to concerns of thrombosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946','lexi-content-ref-25752646']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946','lexi-content-ref-25752646'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; etiology of hypercoagulability has not been elucidated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11727356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11727356'])">Ref</a></span>). Postmarketing reports contain a variety of dosing regimens resulting in insufficient evidence to correlate dose with VTE risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16563066','lexi-content-ref-11727356','lexi-content-ref-25556442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16563066','lexi-content-ref-11727356','lexi-content-ref-25556442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; reports range from 10 days to months of megestrol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16563066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16563066'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cancer patients, especially pancreatic cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25556442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25556442'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Limited mobility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16563066','lexi-content-ref-25556442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16563066','lexi-content-ref-25556442'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting hypercoagulable states (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25556442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25556442'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16563066','lexi-content-ref-25556442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16563066','lexi-content-ref-25556442'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F192285"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (4% to 14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (2% to 5%), hyperglycemia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (3%), flatulence (10%), nausea (4%), vomiting (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (6%), insomnia (4% to 6%), pain (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, diaphoresis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breakthrough bleeding</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Tumor flare</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Lethargy, malaise, mood changes</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (Ruiz 2013), venous thromboembolism (including pulmonary embolism, thrombophlebitis) (Oberhoff 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenocortical insufficiency (Mehta 2015), Cushing syndrome (Delitala 2013), decreased glucose tolerance, diabetes mellitus (Jain 1996), exacerbation of diabetes mellitus, HPA-axis suppression (Mehta 2015), weight gain (Ruiz 2013)</p></div>
<div class="block coi drugH1Div" id="F192301"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to megestrol or any component of the formulation; known or suspected pregnancy (suspension).</p></div>
<div class="block war drugH1Div" id="F192282"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding irregularities: Vaginal bleeding or discharge may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F192294"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Megace ES: 625 mg/5 mL (150 mL [DSC]) [contains alcohol, usp, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg/mL (10 mL [DSC], 240 mL, 480 mL); 400 mg/10 mL (10 mL); 800 mg/20 mL (20 mL); 625 mg/5 mL (5 mL, 150 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 40 mg</p></div>
<div class="block geq drugH1Div" id="F192278"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F2524681"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Megestrol Acetate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $0.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">625 mg/5 mL (per mL): $5.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Megestrol Acetate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.69 - $1.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.28 - $1.71</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867451"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 160 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg</p></div>
<div class="block adm drugH1Div" id="F192298"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Shake suspension well before use.</p>
<p style="text-indent:-2em;margin-left:2em;">The 625 mg/5 mL suspension may be administered without regard to meals.</p></div>
<div class="block admp drugH1Div" id="F52613243"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Oral suspension (40 mg/mL): Shake oral suspension well before administering; the effect of food on the bioavailability of Megace Oral Suspension has not been evaluated.</p></div>
<div class="block hazard drugH1Div" id="F49132799"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F192297"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anorexia or cachexia:</b>
<i>Suspension:</i> Treatment of anorexia, cachexia, or unexplained significant weight loss in patients with AIDS</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Treatment of AIDS-related weight loss should only be initiated after addressing the treatable causes (eg, malignancy, infection, malabsorption, endocrine disease, renal disease, psychiatric disorder) for weight loss. Megestrol is not intended to prevent weight loss.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer:</b>
<i>Tablet:</i> Treatment (palliative) of advanced breast cancer</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial cancer:</b>
<i>Tablet:</i> Treatment (palliative) of advanced endometrial carcinoma</p></div>
<div class="block off-label drugH1Div" id="F25572898"><span class="drugH1">Use: Off-Label: Adult</span><p>Cancer-related cachexia; Endometrial hyperplasia (alternative therapy)</p></div>
<div class="block mst drugH1Div" id="F192337"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Megace may be confused with Reglan</p>
<p style="text-indent:-2em;margin-left:4em;">Megestrol may be confused with mesalamine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Megestrol is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to an increased risk of thrombotic events and potentially death in older adults, with minimal effects on weight (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299657"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F192287"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Progestins may enhance the adverse/toxic effect of Chlorprothixene. Progestins may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: Megestrol may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flotufolastat F18: Antiandrogens may diminish the diagnostic effect of Flotufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of flotufolastat F18 in prostate cancer. The impact of these therapies on the performance of flotufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 PSMA-11: Antiandrogens may diminish the therapeutic effect of Gallium Ga 68 PSMA-11.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of gallium Ga 68 PSMA-11 (gozetotide) in prostate cancer. The impact on the performance of gallium Ga 68 PSMA-11 (gozetotide) is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Progestins may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking progestins.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piflufolastat F18: Antiandrogens may diminish the diagnostic effect of Piflufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of piflufolastat F18 in prostate cancer. The impact of these therapies on the performance of piflufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: May diminish the therapeutic effect of Progestins. Progestins may diminish the therapeutic effect of Ulipristal.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Megestrol may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308132"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to treatment in patients who may become pregnant; effective contraception should be used when treating anorexia or cachexia in patients with HIV infection. In clinical studies, megestrol was shown to cause breakthrough vaginal bleeding.</p>
<p style="text-indent:0em;margin-top:2em;">Megestrol may be used for the nonsurgical management of endometrial intraepithelial neoplasia/atypical endometrial hyperplasia in patients who desire fertility (ACOG 2015; Concin 2021). Pregnancy rates are favorable in patients who respond to treatment (Shikeli 2020; Wang 2019; Yang 2020). Close monitoring is recommended; surgery may be required following pregnancy or in case of treatment failure (Concin 2021).</p></div>
<div class="block pri drugH1Div" id="F4627707"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, megestrol may cause fetal harm if administered during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Use is contraindicated for the treatment of anorexia or cachexia in pregnant patients with HIV infection.</p></div>
<div class="block brc drugH1Div" id="F4627709"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Megestrol is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Information is available from 5 breastfeeding women, ~8 weeks postpartum, who were administered megestrol 4 mg in combination with ethinyl estradiol 50 mcg daily for contraception. Maternal serum and milk samples were obtained over 5 days, beginning 10 days after therapy began. The highest concentrations of megestrol were found at the samples taken 3 hours after the maternal dose. Mean concentrations of megestrol were 6.5 ng/mL (maternal serum; range: 3.7 to 10.8 ng/mL), 4.6 ng/mL (foremilk; range: 1.1 to 12.7 ng/mL), and 5.6 ng/mL (hindmilk; range: 1.2 to 18.5 ng/mL) (Nilsson 1977).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for adverse reaction in the breastfed newborn, the manufacturer recommends discontinuing breastfeeding while receiving megestrol for the treatment of cancer. Due to the potential for HIV transmission, breastfeeding is not recommended when treating anorexia or cachexia associated with HIV infection.</p></div>
<div class="block mop drugH1Div" id="F192292"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Observe for signs of thromboembolic events; blood pressure, weight; serum glucose; signs/symptoms suggestive of adrenal insufficiency with chronic use. Evaluate pregnancy status prior to treatment in patients who may become pregnant.</p>
<p style="text-indent:-2em;margin-left:2em;">Endometrial hyperplasia (off-label use): Assess response to treatment every 3 to 6 months (ACOG 2015; Concin 2021).</p></div>
<div class="block pha drugH1Div" id="F192281"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Megestrol is a synthetic progestin with antiestrogenic properties which disrupt the estrogen receptor cycle. Megestrol interferes with the normal estrogen cycle and results in a lower LH titer. May also have a direct effect on the endometrium. Megestrol is an antineoplastic progestin thought to act through an antileutenizing effect mediated via the pituitary. May stimulate appetite by antagonizing the metabolic effects of catabolic cytokines.</p></div>
<div class="block phk drugH1Div" id="F192300"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Breast or endometrial cancer: At least 2 months of continuous therapy; Weight gain: 2 to 4 weeks</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (to free steroids and glucuronide conjugates)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Suspension: 20 to 50 hours; Tablet: Mean: 34.2 hours (range: 13 to 105 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Suspension: 5 hours; Tablet: 2.2 hours (range: 1 to 3 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (57% to 78%; 5% to 8% as metabolites); feces (8% to 30%) within 10 days</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F192303"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo-megestrol | Megace</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megacorp | Megestrol Servycal | Varigestrol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Apetiz | Megestol | Mestrol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acetato de megestrol | Femigestrol | Gynodal | Megestat</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Megestat</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Megace | Mestrel</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Megace | Xin yi yi ning</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megaplex | Megex I</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megaplex</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Megestat</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megestrol | Varigestrol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Borea | Maygace | Megefren</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megeron | Megestin | Niagestin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megesin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megostat</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cachexi | Megace | Megesin | Megestrol pharmacenter | Megyrina</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megaplex | Mg 40 | Tracetate</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Celstrol | Cravihenz | Endace | Megasty | Megeetron | Mestrolyst | Mhega | Ridoxia | Unistrol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Gestroltex | Megace | Megestil | Megestrolo pht | Megexia</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Daewon megetrol es | Megace | Megace F | Megaprex | Megerol | Megesia | Megestar | Megestrol | Megestrol acetate daewon | Megetrol | Neoxia</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Borea | Maygace altas dosis | Megace</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Borea | Megace | Megaplex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megestrol | Mestrel</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo-megestrol | Megace</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megestrol | Megestrolacetaat focus</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Borea | Megace | Megestil</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo-megestrol | Megace</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megestrol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cachexan | Gestrol | Megace | Megalia | Megastril | Megesin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megace oral suspension</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Acestrol | Megace | Megestrol Aps | Xolbe</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Acetato de megestrol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megaplex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-megestrol | Megace</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Megace | Niagestin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo-megestrol | Megace</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megaplex | Megesin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Giga | Megace | Megaplex | Megrol | Mestrel</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Megace</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Borea | Megace</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Giga | Megace | Megaplex | Megatus | Megaxia es | Megejohn | Megest | Mekei</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megaplex | Megestrol vista</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Megace | Megastrol | Megestrol | Megestrol Servycal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30693946">
<a name="30693946"></a>2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. <i>J Am Geriatr Soc</i>. 2019;67(4):674-694. doi: 10.1111/jgs.15767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/30693946/pubmed" id="30693946" target="_blank">30693946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25932867">
<a name="25932867"></a>American College of Obstetricians and Gynecologists (ACOG) Committee. The American College of Obstetricians and Gynecologists Committee opinion no. 631. Endometrial intraepithelial neoplasia. <i>Obstet Gynecol</i>. 2015;125(5):1272-1278. doi:10.1097/01.AOG.0000465189.50026.20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/25932867/pubmed" id="25932867" target="_blank">25932867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22863972">
<a name="22863972"></a>Armstrong AJ, Hurd WW, Elguero S, Barker NM, Zanotti KM. Diagnosis and management of endometrial hyperplasia. <i>J Minim Invasive Gynecol.</i> 2012;19(5):562-571. doi:10.1016/j.jmig.2012.05.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/22863972/pubmed" id="22863972" target="_blank">22863972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8853762">
<a name="8853762"></a>Azcona C, Castro L, Crespo E, Jiménez M, Sierrasesúmaga L. Megestrol acetate therapy for anorexia and weight loss in children with malignant solid tumours. <i>Aliment Pharmacol Ther</i>. 1996;10(4):577-586.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/8853762/pubmed" id="8853762" target="_blank">8853762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baby.2021">
<a name="Baby.2021"></a>Baby M, Murthy DB, Litao MK, Shust G, Shah BC. Exogenous Cushing's syndrome, hypogonadism and diabetes secondary to megestrol acetate. <i>Journal of the Endocrine Society</i>. 2021;5(1):A700. doi:10.1210/jendso/bvab048</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9137798">
<a name="9137798"></a>Beller E, Tattersall M, Lumley T, et al. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group. <i>Ann Oncol</i>. 1997;8(3):277-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/9137798/pubmed" id="9137798" target="_blank">9137798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet.</i> 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7970985">
<a name="7970985"></a>Brady MT, Koranyi KI, Hunkler JA. Megestrol acetate for treatment of anorexia associated with human immunodeficiency virus infection in children. <i>Pediatr Infect Dis J</i>. 1994;13(8):754-756.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/7970985/pubmed" id="7970985" target="_blank">7970985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9041287">
<a name="9041287"></a>Clarick RH, Hanekom WA, Yogev R, Chadwick EG. Megestrol acetate treatment of growth failure in children infected with human immunodeficiency virus. <i>Pediatrics</i>. 1997;99(3):354-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/9041287/pubmed" id="9041287" target="_blank">9041287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33604759">
<a name="33604759"></a>Concin N, Creutzberg CL, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>Virchows Arch</i>. 2021;478(2):153-190. doi:10.1007/s00428-020-03007-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/33604759/pubmed" id="33604759" target="_blank">33604759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24167059">
<a name="24167059"></a>Cuvelier GD, Baker TJ, Peddie EF, et al. A randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy. <i>Pediatr Blood Cancer</i>. 2014;61(4):672-679.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/24167059/pubmed" id="24167059" target="_blank">24167059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25752646">
<a name="25752646"></a>Davidoff AJ, Miller GE, Sarpong EM, Yang E, Brandt N, Fick DM. Prevalence of potentially inappropriate medication use in older adults using the 2012 Beers criteria. <i>J Am Geriatr Soc</i>. 2015;63(3):486-500. doi:10.1111/jgs.13320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/25752646/pubmed" id="25752646" target="_blank">25752646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23412818">
<a name="23412818"></a>Delitala AP, Fanciulli G, Maioli M, Piga G, Delitala G. Primary symptomatic adrenal insufficiency induced by megestrol acetate. <i>Neth J Med</i>. 2013;71(1):17-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/23412818/pubmed" id="23412818" target="_blank">23412818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12006958">
<a name="12006958"></a>Eubanks V, Koppersmith N, Wooldridge N, et al, “Effects of Megestrol Acetate on Weight Gain, Body Composition, and Pulmonary Function in Patients With Cystic Fibrosis,” <i>J Pediatr</i>, 2002, 140(4):439-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/12006958/pubmed" id="12006958" target="_blank">12006958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10375262">
<a name="10375262"></a>Farrar DJ, "Megestrol Acetate: Promises and Pitfalls," <i>AIDS Patient Care STDS</i>, 1999, 13(3):149-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/10375262/pubmed" id="10375262" target="_blank">10375262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20934679">
<a name="20934679"></a>Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. <i>Am J Obstet Gynecol</i>. 2010;203(6):547.e1-10. doi:10.1016/j.ajog.2010.07.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/20934679/pubmed" id="20934679" target="_blank">20934679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22245711">
<a name="22245711"></a>Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. <i>Gynecol Oncol</i>. 2012;125(2):477-482. doi:10.1016/j.ygyno.2012.01.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/22245711/pubmed" id="22245711" target="_blank">22245711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20430646">
<a name="20430646"></a>Hobbs DJ, Bunchman TE, Weismantel DP, et al. Megestrol acetate improves weight gain in pediatric patients with chronic kidney disease. <i>J Ren Nutr</i>. 2010;20(6):408-413.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/20430646/pubmed" id="20430646" target="_blank">20430646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8758019">
<a name="8758019"></a>Jain P, Girardi LS, Sherman L, Berelowicz M, Smith LG. Insulin resistance and development of diabetes mellitus associated with megestrol acetate therapy. <i>Postgrad Med J</i>. 1996;72(848):365-367. doi:10.1136/pgmj.72.848.365.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/8758019/pubmed" id="8758019" target="_blank">8758019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23349204">
<a name="23349204"></a>Kwan L, Yip T, Lui SL, Chan TM, Lo WK. Adrenal insufficiency in a peritoneal dialysis patient taking megestrol acetate. <i>Perit Dial Int.</i> 2013;33(1):105-107. doi:10.3747/pdi.2012.00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/23349204/pubmed" id="23349204" target="_blank">23349204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35851863">
<a name="35851863"></a>Kwon MK, Kim J, Ahn J, et al. Clinical features and risk factors of adrenal insufficiency in patients with cancer admitted to the hospitalist-managed medical unit. <i>J Korean Med Sci</i>. 2022;37(28):e222. doi:10.3346/jkms.2022.37.e222.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/35851863/pubmed" id="35851863" target="_blank">35851863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8636744">
<a name="8636744"></a>Lentz SS, Brady MF, Major FJ, et al, “High-Dose Megestrol Acetate in Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study,” <i>J Clin Oncol</i>, 1996, 14(2):357-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/8636744/pubmed" id="8636744" target="_blank">8636744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34286938">
<a name="34286938"></a>Liles AM, Jenkins AB, Hendrix H, Johnson E, Rowe H, McClendon KS. Appetite stimulants for treatment of protein energy wasting of chronic kidney disease. <i>Nephrol Nurs J.</i> 2021;48(3):267-273.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/34286938/pubmed" id="34286938" target="_blank">34286938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2193166">
<a name="2193166"></a>Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. <i>J Natl Cancer Inst</i>. 1990;82(13):1127-1132. doi:10.1093/jnci/82.13.1127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/2193166/pubmed" id="2193166" target="_blank">2193166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10506633">
<a name="10506633"></a>Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. <i>J Clin Oncol</i>. 1999;17(10):3299-3306. doi:10.1200/JCO.1999.17.10.3299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/10506633/pubmed" id="10506633" target="_blank">10506633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8478668">
<a name="8478668"></a>Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. <i>J Clin Oncol</i>. 1993;11(4):762-767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/8478668/pubmed" id="8478668" target="_blank">8478668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10997370">
<a name="10997370"></a>Marchand V, Baker SS, Stark TJ, Baker RD. Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. <i>J Pediatr Gastroenterol Nutr</i>. 2000;31(3):264-269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/10997370/pubmed" id="10997370" target="_blank">10997370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16563066">
<a name="16563066"></a>Marshall LL. Megestrol acetate therapy in geriatric patients: case reviews and associated deep vein thrombosis. <i>Consult Pharm</i>. 2003;18(9):764-773.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/16563066/pubmed" id="16563066" target="_blank">16563066</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Megace (megestrol acetate oral suspension) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Megestrol.1">
<a name="Megestrol.1"></a>Megestrol acetate oral suspension [prescribing information]. East Brunswick, NJ: Strides Pharma Inc; March 2022.</div>
</li>
<li>
<div class="reference">
                  Megestrol tablets [prescribing information]. Livonia, MI: Major Pharmaceuticals; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26770843">
<a name="26770843"></a>Mehta K, Weiss I, Goldberg MD. Megace mystery: A case of central adrenal insufficiency. <i>Case Rep Endocrinol</i>. 2015;2015:147265. doi:10.1155/2015/147265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/26770843/pubmed" id="26770843" target="_blank">26770843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27218795">
<a name="27218795"></a>Nanjappa S, Thai C, Shah S, Snyder M. Pharmacy report: Megestrol acetate-induced adrenal insufficiency. <i>Cancer Control</i>. 2016;23(2):167-169. doi:10.1177/107327481602300212<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/27218795/pubmed" id="27218795" target="_blank">27218795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10536070">
<a name="10536070"></a>Nasr SZ, Hurwitz ME, Brown RW, et al, “Treatment of Anorexia and Weight Loss With Megestrol Acetate in Patients With Cystic Fibrosis,” <i>Pediatr Pulmonol</i>, 1999, 28(5):380-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/10536070/pubmed" id="10536070" target="_blank">10536070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-606501">
<a name="606501"></a>Nilsson S, Nygren KG, Johansson ED. Megestrol acetate concentrations in plasma and milk during administration of an oral contraceptive containing 4 mg megestrol acetate to nursing women. <i>Contraception</i>. 1977;16(6):615-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/606501/pubmed" id="606501" target="_blank">606501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11727356">
<a name="11727356"></a>Oberhoff C, Hoffmann O, Winkler UH, Schindler AE. Hemostatic effects of high-dose megestrol acetate therapy in patients with advanced gynecological cancer. <i>Gynecol Endocrinol</i>. 2001;15(5):341-348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/11727356/pubmed" id="11727356" target="_blank">11727356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25556442">
<a name="25556442"></a>Ordu C, Pilanci KN, Koksal UI, et al. Can megestrol acetate induce thrombosis in advanced oncology patients receiving chemotherapy? <i>Asian Pac J Cancer Prev</i>. 2014;15(23):10165-10169. doi:10.7314/apjcp.2014.15.23.10165.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/25556442/pubmed" id="25556442" target="_blank">25556442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12872362">
<a name="12872362"></a>Orme LM, Bond JD, Humphrey MS, et al. Megestrol acetate in pediatric oncology patients may lead to severe, symptomatic adrenal suppression. <i>Cancer</i>. 2003;98(2):397-405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/12872362/pubmed" id="12872362" target="_blank">12872362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9277658">
<a name="9277658"></a>Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. <i>Obstet Gynecol</i>. 1997;90(3):434-440. doi:10.1016/s0029-7844(97)00297-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/9277658/pubmed" id="9277658" target="_blank">9277658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32432946">
<a name="32432946"></a>Roeland EJ, Bohlke K, Baracos VE, et al. Management of cancer cachexia: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(21):2438-2453. doi:10.1200/JCO.20.00611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/32432946/pubmed" id="32432946" target="_blank">32432946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23543530">
<a name="23543530"></a>Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. <i>Cochrane Database Syst Rev</i>. 2013;3:CD004310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/23543530/pubmed" id="23543530" target="_blank">23543530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27690687">
<a name="27690687"></a>Sharifzadeh F, Aminimoghaddam S, Kashanian M, Fazaeli M, Sheikhansari N. A comparison between the effects of metformin and megestrol on simple endometrial hyperplasia. <i>Gynecol Endocrinol</i>. 2017;33(2):152-155. doi:10.1080/09513590.2016.1223285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/27690687/pubmed" id="27690687" target="_blank">27690687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32569453">
<a name="32569453"></a>Shikeli S, Gowri V, Rawahi TA. Fertility-sparing treatment in young women with atypical endometrial hyperplasia and low-grade endometrial cancer: a Tertiary Center experience. <i>JBRA Assist Reprod</i>. 2020;24(4):466-469. doi:10.5935/1518-0557.20200037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/32569453/pubmed" id="32569453" target="_blank">32569453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9066597">
<a name="9066597"></a>Strang P, “The Effect of Megestrol Acetate on Anorexia, Weight Loss and Cachexia in Cancer and AIDS Patients,” <i>Anticancer Res</i>, 1997, 17(1B):657-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/9066597/pubmed" id="9066597" target="_blank">9066597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32652300">
<a name="32652300"></a>Tehranian A, Ghahghaei-Nezamabadi A, Arab M, Khalagi K, Aghajani R, Sadeghi S. The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial. <i>J Gynecol Obstet Hum Reprod</i>. 2021;50(6):101863. doi:10.1016/j.jogoh.2020.101863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/32652300/pubmed" id="32652300" target="_blank">32652300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23090535">
<a name="23090535"></a>Trimble CL, Method M, Leitao M, et al; Society of Gynecologic Oncology Clinical Practice Committee. Management of endometrial precancers. <i>Obstet Gynecol.</i> 2012;120(5):1160-1175. doi:10.1097/AOG.0b013e31826bb121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/23090535/pubmed" id="23090535" target="_blank">23090535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ullrich.1">
<a name="Ullrich.1"></a>Ullrich C, Duncan J, Joselow M, Wolfe J. Pediatric palliative care. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 7.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9708631">
<a name="9708631"></a>Vadell C, Seguí MA, Giménez-Arnau JM, et al. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. <i>Am J Clin Oncol</i>. 1998;21(4):347-351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/9708631/pubmed" id="9708631" target="_blank">9708631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30826750">
<a name="30826750"></a>Wang Y, Zhou R, Wang H, Liu H, Wang J. Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia. <i>Int J Gynecol Cancer</i>. 2019;29(4):699-704. doi:10.1136/ijgc-2018-000081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/30826750/pubmed" id="30826750" target="_blank">30826750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26776251">
<a name="26776251"></a>Wazny LD, Nadurak S, Orsulak C, Giles-Smith L, Tangri N. The efficacy and safety of megestrol acetate in protein-energy wasting due to chronic kidney disease: a systematic review. <i>J Ren Nutr.</i> 2016;26(3):168-176. doi:10.1053/j.jrn.2015.11.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/26776251/pubmed" id="26776251" target="_blank">26776251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31961463">
<a name="31961463"></a>Yang BY, Gulinazi Y, Du Y, et al. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. <i>BJOG</i>. 2020;127(7):848-857. doi:10.1111/1471-0528.16108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/megestrol-acetate-drug-information/abstract-text/31961463/pubmed" id="31961463" target="_blank">31961463</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9603 Version 365.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
